July 12, 2020

The Niche

Knoepfler lab stem cell blog

Vision

Vision research and vision loss

3 min read

Clinical trials using organoids are still rare and a Clinicaltrials.gov search for such organoid work largely brings up in vitro studies. A new clinical study in Japan where organoid material will actually be transplanted into patients is causing a lot of excitement. Masayo Takahashi (高橋 政代) is a pioneer in stem cell-based clinical trial work and more specifically induced pluripotent stem cell (IPSC)-based trials. Her new clinical study is another groundbreaking step in that it is organoid based, in this case for Retinitis pigmentosa. …Read More

3 min read

The NIH announced the launch of the 1st autologous induced pluripotent stem (IPS) cell trial for vision loss in the U.S., focused on macular degeneration. The protocol is based on a solid foundation of pre-clinical animal studies: “Researchers at the National Eye Institute (NEI) are launching a clinical trial to test the safety of a novel patient-specific stem cell-based therapy to treat geographic atrophy, the advanced “dry” form of age-related macular degeneration (AMD), a leading cause of vision loss among people age 65 and …Read More

2 min read

365 days a year, 24 hours a day stem cells are growing in labs around the world, providing a never-ending stream of data and products, with real hope, good news, and lots of surprises. You can see some past examples of good news in the stem cell and regenerative medicine field highlighted on The Niche here. Today’s post brings 2 examples of recent good news and a brain organoid surprise. And one bonus more about space and when you’d run out of air (or not …Read More

3 min read

With stem cells for vision loss, first we want to be sure a treatment won’t make things worse. Several teams around the globe are rigorously studying stem cell-based approaches to vision loss via regulatory-compliant studies including for macular degeneration with some results cautiously upbeat on safety from early phase analyses, but data from a new study on the use of human embryonic stem cell (hESC)-derived retinal pigmented epithelial cells (RPEs) for macular degeneration are concerning in some ways. The paper in the AAO Journal from a …Read More